摘要
目的:评价低剂量利妥昔单抗(RTX)用于儿童激素依赖型肾病综合征(SDNS)或频繁复发型肾病综合征(FRNS)的有效性和安全性。方法:收集我院肾脏免疫科2020年1月至2022年7月应用RTX治疗的SDNS和FRNS患儿临床资料,包括患儿性别、年龄、持续缓解时间、RTX使用前1年与治疗1年后的复发次数以及糖皮质激素、他克莫司的使用剂量,并将RTX治疗前后相关指标进行统计分析。结果:共收集31例SDNS/FRNS患儿,起病年龄为5.0(3.2,9.5)岁,初始使用RTX的年龄为(10.0±0.7)岁,随访时间为1.1(1.0,1.5)年。与使用RTX治疗前相比,RTX治疗1年后复发次数、糖皮质激素以及他克莫司的使用剂量均降低(P<0.01)。超敏反应是最常见的不良反应,无因感染导致死亡的病例发生。结论:对于SDNS/FRNS患儿,低剂量RTX治疗方案展现出良好的有效性及安全性。
Objective:To evaluate the efficacy and safety of low-dose rituximab(RTX)in children with steroid-dependent nephrotic syndrome(SDNS)or frequent recurrent nephrotic syndrome(FRNS).Methods:Clinical data of SDNS/FRNS children treated with RTX from Jan.2020 to Jul.2022 in the Department of Nephrology and Immunology at Children’s Hospital of Soochow University were retrospectively analyzed,including gender,age,duration of sustained remission,annual recurrence frequency before and after RTX treatment,and dosage adjustment of glucocorticoids and tacrolimus.Relevant indicators before and after RTX treatment were statistically analyzed.Results:A total of 31 SDNS/FRNS children were enrolled,with disease onset at 5.0(3.2,9.5)years and initial RTX administration age of(10.0±0.73)years.The median follow-up duration was 1.1(1.0,1.5)years.Compared with before RTX treatment,annual recurrence frequency and dosage of glucocorticoids and tacrolimus decreased after RTX treatment(P<0.01).Hypersensitivity reactions were the most common adverse drug reactions,with no infection-related fatalities reported.Conclusion:Low-dose RTX demonstrates favorable therapeutic efficacy and safety profiles in children with SDNS/FRNS.
作者
姚华
朱增燕
李桂凤
王凤娇
Yao Hua;Zhu Zengyan;Li Guifeng;Wang Fengjiao(Children’s Hospital of Soochow University,Jiangsu Suzhou 215000,China)
出处
《儿科药学杂志》
2025年第9期39-41,共3页
Journal of Pediatric Pharmacy
基金
江苏省药学会-天晴医院药学基金,编号Q202120。
